Integrin Research The Martin Humphries Lab

Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors

The continued corona virus illness 2019 (COVID-19) pandemic, brought on by SARS-CoV-2 an infection, has resulted in a whole bunch of hundreds of deaths. Mobile entry of SARS-CoV-2, which is mediated by the viral spike protein and ACE2 receptor, is a necessary goal for the event of vaccines, therapeutic antibodies, and medicines. Utilizing a mammalian cell expression system, a genetically engineered sensor of fluorescent protein (Gamillus)-fused SARS-CoV-2 spike trimer (STG) to probe the viral entry course of is developed.

In ACE2-expressing cells, it’s discovered that the STG probe has glorious efficiency within the live-cell visualization of receptor binding, mobile uptake, and intracellular trafficking of SARS-CoV-2 underneath virus-free situations. The brand new system permits quantitative analyses of the inhibition potentials and detailed affect of COVID-19-convalescent human plasmas, neutralizing antibodies and compounds, offering a flexible software for high-throughput screening and phenotypic characterization of SARS-CoV-2 entry inhibitors. This strategy might also be tailored to develop a viral entry visualization system for different viruses.

The position of therapeutic plasma trade in clinically amyopathic dermatomyositis with MDA-5 antibody: A case report and assessment of the literature

Clinically amyopathic dermatomyositis (CADM) is a uncommon, aggressive variant of dermatomyositis related to interstitial lung illness (ILD) and refractoriness to immunosuppressants. Antibodies towards melanoma differentiation-associated gene 5 (MDA-5) are sometimes present in sufferers with CADM. We report a affected person with superior CADM with ILD and MDA-5 antibodies who failed to enhance with immunosuppressants. We carried out 2 TPE over three days, utilizing 5% albumin as alternative fluid.

Though 5 complete TPE had been deliberate, he was transferred for lung transplant analysis after the second TPE; he died 16 days after switch with out receiving a transplant. A literature assessment recognized 4 sufferers with CADM and MDA-5 antibodies handled with TPE; all skilled symptomatic enchancment of their ILD. We attribute our affected person’s final result to the superior nature of his illness quite than a failure of TPE. Further analysis could point out a attainable reclassification of CADM with MDA-5 antibodies in future ASFA tips.

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Size Protein for Concentrating on Mouse Dendritic Cells In Vitro and In Vivo

Focused antigen supply to cross-presenting dendritic cells (DC) in vivo effectively induces T effector cell responses and shows a beneficial strategy in vaccine design. Antigen is delivered to DC by way of antibodies particular for endocytosis receptors corresponding to DEC-205 that induce uptake, processing, and MHC class I- and II-presentation. Environment friendly and dependable conjugation of the specified antigen to an acceptable antibody is a essential step in DC concentrating on and amongst different components is determined by the format of the antigen. Chemical conjugation of full-length protein to purified antibodies is one attainable technique. Prior to now, we have now efficiently established cross-linking of the mannequin antigen ovalbumin (OVA) and a DEC-205-specific IgG2a antibody (αDEC-205) for in vivo DC concentrating on research in mice.

Step one of the protocol is the purification of the antibody from the supernatant of the NLDC (non-lymphoid dendritic cells)-145 hybridoma by affinity chromatography. The purified antibody is activated for chemical conjugation by sulfo-SMCC (sulfosuccinimidyl 4-[N-maleimidomethyl] cyclohexane-1-carboxylate) whereas on the similar time the sulfhydryl-groups of the OVA protein are uncovered via incubation with TCEP-HCl (tris (2-carboxyethyl) phosphine hydrochloride).

Extra TCEP-HCl and sulfo-SMCC are eliminated and the antigen is combined with the activated antibody for in a single day coupling. The ensuing αDEC-205/OVA conjugate is concentrated and free of unbound OVA. Profitable conjugation of OVA to αDEC-205 is verified by western blot evaluation and enzyme-linked immunosorbent assay (ELISA). We’ve got efficiently used chemically crosslinked αDEC-205/OVA to induce cytotoxic T cell responses within the liver and to check completely different adjuvants for his or her potential in inducing humoral and mobile immunity following in vivo concentrating on of DEC-205⁺ DC.

Past that, such chemically coupled antibody/antigen conjugates provide beneficial instruments for the environment friendly induction of vaccine responses to tumor antigens and have been confirmed to be superior to classical immunization approaches relating to the prevention and remedy of assorted varieties of tumors.

Excessive seroprevalence of anti-Fasciola antibody amongst cattle farm staff and dwellers in Kelantan

Human fascioliasis is a public well being drawback significantly in areas the place ruminants are raised. The goals of this research had been to find out the seroprevalence of anti-Fasciola antibody and the related danger components amongst cattle farm staff and dwellers in Kelantan.

A complete of 90 blood samples had been collected on this cross-sectional research. A set of validated questionnaire was used to acquire data on socio-demographic profiles and dietary habits of members. The sera had been subjected to enzyme linked immunosorbent assay (ELISA) for the detection of anti-Fasciola IgG antibody. The affiliation between seropositivity and the numerous danger components had been decided by way of logistic regression. From the consequence, serological screening revealed 60 (67%) members optimistic for anti-Fasciola IgG antibody.

VEGF-A(VEGF/1063) Antibody
BNC811063-100	Biotium	100uL	EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC811063-500	Biotium	500uL	EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC701063-100	Biotium	100uL	EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC701063-500	Biotium	500uL	EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC881063-100	Biotium	100uL	EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC881063-500	Biotium	500uL	EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC611063-100	Biotium	100uL	EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC611063-500	Biotium	500uL	EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC681063-100	Biotium	100uL	EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC681063-500	Biotium	500uL	EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCA1063-250	Biotium	250uL	EUR 383
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNUM1063-50	Biotium	50uL	EUR 395
Description: Primary antibody against VEGF-A(VEGF/1063), 1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC051063-100	Biotium	100uL	EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC051063-500	Biotium	500uL	EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCP1063-250	Biotium	250uL	EUR 383
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCR1063-250	Biotium	250uL	EUR 383
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNUB1063-100	Biotium	100uL	EUR 209
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL

VEGF-A(VEGF/1063) Antibody
BNUB1063-500	Biotium	500uL	EUR 458
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL

VEGF-A(VEGF/1063) Antibody
BNC431063-100	Biotium	100uL	EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC431063-500	Biotium	500uL	EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCB1063-100	Biotium	100uL	EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCB1063-500	Biotium	500uL	EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCH1063-100	Biotium	100uL	EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCH1063-500	Biotium	500uL	EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC551063-100	Biotium	100uL	EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC551063-500	Biotium	500uL	EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC941063-100	Biotium	100uL	EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC941063-500	Biotium	500uL	EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC801063-100	Biotium	100uL	EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC801063-500	Biotium	500uL	EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC401063-100	Biotium	100uL	EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC401063-500	Biotium	500uL	EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL

Mouse VEGF-A Recombinant Protein
R00045-4	BosterBio	5ug/vial	EUR 259
Description: VEGF-A is member of the family of vascular endothelial growth factor (VEGF) proteins, which stimulate vasculogenesis and angiogenesis to restore oxygen supply to tissues. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF). Mouse VEGF-A Recombinant Protein is purified vascular endothelial growth factor A produced in yeast.

Recombinant Mouse VEGF-A/VEGF164
CX73-10ug	Novoprotein	10ug	EUR 202
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Recombinant Mouse VEGF-A/VEGF164
CX73-1mg	Novoprotein	1mg	EUR 2486
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Recombinant Mouse VEGF-A/VEGF164
CX73-500ug	Novoprotein	500ug	EUR 1613
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Recombinant Mouse VEGF-A/VEGF164
CX73-50ug	Novoprotein	50ug	EUR 496
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Rabbit Polyclonal antibody Anti-CRBN
Anti-CRBN	ImmunoStep	50 µg	EUR 349

VEGF-A Polyclonal Antibody
ES7496-100ul	ELK Biotech	100ul	EUR 279
Description: A Rabbit Polyclonal antibody against VEGF-A from Human/Mouse/Rat. This antibody is tested and validated for IHC, WB, ELISA

VEGF-A Polyclonal Antibody
ES7496-50ul	ELK Biotech	50ul	EUR 207
Description: A Rabbit Polyclonal antibody against VEGF-A from Human/Mouse/Rat. This antibody is tested and validated for IHC, WB, ELISA

VEGF-A Polyclonal Antibody
ES3838-100ul	ELK Biotech	100ul	EUR 279
Description: A Rabbit Polyclonal antibody against VEGF-A from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

VEGF-A Polyclonal Antibody
ES3838-50ul	ELK Biotech	50ul	EUR 207
Description: A Rabbit Polyclonal antibody against VEGF-A from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

VEGF-A Polyclonal Antibody
ABP56497-003ml	Abbkine	0.03ml	EUR 158
Description: A polyclonal antibody for detection of VEGF-A from Human, Mouse, Rat. This VEGF-A antibody is for IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human VEGF-A

VEGF-A Polyclonal Antibody
ABP56497-01ml	Abbkine	0.1ml	EUR 289
Description: A polyclonal antibody for detection of VEGF-A from Human, Mouse, Rat. This VEGF-A antibody is for IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human VEGF-A

VEGF-A Polyclonal Antibody
ABP56497-02ml	Abbkine	0.2ml	EUR 414
Description: A polyclonal antibody for detection of VEGF-A from Human, Mouse, Rat. This VEGF-A antibody is for IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human VEGF-A

VEGF-A Polyclonal Antibody
ABP52839-003ml	Abbkine	0.03ml	EUR 158
Description: A polyclonal antibody for detection of VEGF-A from Human. This VEGF-A antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human VEGF-A

VEGF-A Polyclonal Antibody
ABP52839-01ml	Abbkine	0.1ml	EUR 289
Description: A polyclonal antibody for detection of VEGF-A from Human. This VEGF-A antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human VEGF-A

VEGF-A Polyclonal Antibody
ABP52839-02ml	Abbkine	0.2ml	EUR 414
Description: A polyclonal antibody for detection of VEGF-A from Human. This VEGF-A antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human VEGF-A

VEGF-A Polyclonal Antibody
41552-100ul	SAB	100ul	EUR 252

VEGF-A Polyclonal Antibody
41552-50ul	SAB	50ul	EUR 187

VEGF-A Recombinant Protein
91-069	ProSci	0.05 mg	EUR 684.5
Description: Human Vascular endothelial growth factor (VEGF), also known as VEGF-A and vascular permeability factor (VPF), belongs to the platelet-derived growth factor family of cysteine-knot growth factors. It is a potent activator in vasculogenesis and angiogenesis both physiologically and pathologically. VEGF-A has 8 differently spliced isoforms, of which VEGF165 is the most abundant one. VEGF165 is a disulfide-linked homodimer consisting of two glycosylated 165 amino acid polypeptide chains. VEGF stimulates the cellular response through binding to tyrosine kinase receptors VEGFR1 and VEGFR2 on the cell surface. It is widely accepted that VEGFR2 mediate almost all of the known cellular responses to VEGF while the function of VEGFR1 is less defined and is thought to modulate the VEGFR2 signaling.

VEGF-A Recombinant Protein
91-584	ProSci	0.05 mg	EUR 684.5
Description: Human VEGF121, also known as Vascular endothelial growth factor A, VEGFA, Vascular permeability factor, VPF and VEGF, is a homodimeric, heparin-binding glycoprotein which belongs to the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis, permeabilization of blood vessels and endothelial cell growth, increasing microvascular permeability, promoting cell migration and inhibiting apoptosis. Alternatively spliced transcript variants of VEGF-A encod either secreted or cell-associated isoforms. The lymphangiogenesis may be promoted by upregulation of VEGF121, which may in turn act in part via induction of VEGF-C. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.

VEGF-A Recombinant Protein
91-589	ProSci	0.05 mg	EUR 684.5
Description: Human VEGF121, also known as Vascular endothelial growth factor A, VEGFA, Vascular permeability factor, VPF and VEGF, is a homodimeric, heparin-binding glycoprotein which belongs to the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis, permeabilization of blood vessels and endothelial cell growth, increasing microvascular permeability, promoting cell migration and inhibiting apoptosis. Alternatively spliced transcript variants of VEGF-A encod either secreted or cell-associated isoforms. The lymphangiogenesis may be promoted by upregulation of VEGF121, which may in turn act in part via induction of VEGF-C. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.

VEGF-A Recombinant Protein
91-944	ProSci	0.05 mg	EUR 684.5
Description: Mouse Vascular endothelial growth factor (VEGF or VEGF­A), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the PDGF/VEGF growth factor family that is characterized by a cystine knot structure formed by eight conserved cysteine residues. Alternately spliced isoforms of 120, 164 and 188 aa found in mouse. VEGF binds the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt­1) and VEGF R2 (Flk­/KDR) on endothelial cells.Although affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity. VEGF is required during embryogenesis to regulate the proliferation, migration, and survival of endothelial cells.It may play a role in increasing vascular permeability during lactation, when increased transport of molecules from the blood is required for efficient milk protein synthesis.

VEGF-A Recombinant Protein
92-494	ProSci	0.05 mg	EUR 684.5
Description: Vascular endothelial growth factor (VEGF/VEGF-A ) is originally known as vascular permeability factor (VPF). It belongs to the PDGF family with a cysteine-knot structure comprised of eight conserved cysteine residues, and reckoned as a potent mediator in the process of angiogenesis and vasculogenesis in either fetus or adult. VEGF is particularly expressed in supraoptic , paraventricular nuclei and the choroid plexus of the pituitary, and abundant in the corpus luteum of the ovary and in kidney glomeruli. The rat VEGF protein contains a putative 20 amino acids (aa) signal peptide, and alternative splicing of rat VEGF gene produces isoforms of 120, 144, 164 and 188 aa. Rat VEGF164 respectively displays 97% and 88% aa identity with that regions of mouse and human VEGF. VEGF can bind to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin, and play important roles in inducing endothelial cell proliferation, promoting cell migration, inhibiting apoptosis and inducing permeabilization of blood vessels.

Chicken Anti-Human+Mouse IgG+A+M IgG/Y
HGAM11-A	Alpha Diagnostics	100 ul	EUR 482

Rabbit Anti-Mouse prepro Orexin A IgG # 1, aff pure
PPOX11-A	Alpha Diagnostics	100 ul	EUR 482

Rabbit Anti-Mouse a-1-Acid Glycoprotein IgG, aff pure
A1AG18-A	Alpha Diagnostics	100 ug	EUR 482

Rabbit Anti-Mouse Apolipoprotein A-I protein IgG, aff pure
APOA13-A	Alpha Diagnostics	100 ug	EUR 482

Anti-VEGF antibody
STJ119887	St John's Laboratory	100 µl	EUR 393
Description: This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.

Anti-VEGF antibody
STJ97787	St John's Laboratory	200 µl	EUR 197
Description: Rabbit polyclonal to VEGF.

anti- VEGF antibody
FNab09391	FN Test	100µg	EUR 548.75
Description: Antibody raised against VEGF

Anti- VEGF antibody
FNab09933	FN Test	100µg	EUR 548.75
Description: Antibody raised against VEGF

Anti-VEGF antibody
PAab09391	Lifescience Market	100 ug	EUR 386

Chicken Anti-Protein A IgG, aff pure
PRTA11-A	Alpha Diagnostics	1 mg	EUR 482

Goat Anti-Protein-A IgG aff pure
PRTA12-A	Alpha Diagnostics	0.1 ml	EUR 408

Chicken Anti-Protein-A IgG aff pure
PRTA13-A	Alpha Diagnostics	100 ug	EUR 408

Goat Anti-Human Apolipoprotein A-IV A(ApoA4) peptid IgG, aff pure
APOA45-A	Alpha Diagnostics	100 ul	EUR 482

Bovine VEGF-A Recombinant Protein
R00045	BosterBio	5ug/vial	EUR 259
Description: VEGF-A is member of the family of vascular endothelial growth factor (VEGF) proteins, which stimulate vasculogenesis and angiogenesis to restore oxygen supply to tissues. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF). Bovine VEGF-A Recombinant Protein is purified vascular endothelial growth factor A produced in yeast.

Canine VEGF-A Recombinant Protein
R00045-1	BosterBio	5ug/vial	EUR 259
Description: VEGF-A is member of the family of vascular endothelial growth factor (VEGF) proteins, which stimulate vasculogenesis and angiogenesis to restore oxygen supply to tissues. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF). Canine VEGF-A Recombinant Protein is purified vascular endothelial growth factor A produced in yeast.

Equine VEGF-A Recombinant Protein
R00045-2	BosterBio	5ug/vial	EUR 259
Description: VEGF-A is member of the family of vascular endothelial growth factor (VEGF) proteins, which stimulate vasculogenesis and angiogenesis to restore oxygen supply to tissues. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF). Equine VEGF-A Recombinant Protein is purified vascular endothelial growth factor A produced in yeast.

Feline VEGF-A Recombinant Protein
R00045-3	BosterBio	5ug/vial	EUR 259
Description: VEGF-A is member of the family of vascular endothelial growth factor (VEGF) proteins, which stimulate vasculogenesis and angiogenesis to restore oxygen supply to tissues. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF). Feline VEGF-A Recombinant Protein is purified vascular endothelial growth factor A produced in yeast.

Ovine VEGF-A Recombinant Protein
R00045-5	BosterBio	5ug/vial	EUR 259
Description: VEGF-A is member of the family of vascular endothelial growth factor (VEGF) proteins, which stimulate vasculogenesis and angiogenesis to restore oxygen supply to tissues. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF). Ovine VEGF-A Recombinant Protein is purified vascular endothelial growth factor A produced in yeast.

Rabbit VEGF-A Recombinant Protein
R00045-6	BosterBio	5ug/vial	EUR 259
Description: VEGF-A is member of the family of vascular endothelial growth factor (VEGF) proteins, which stimulate vasculogenesis and angiogenesis to restore oxygen supply to tissues. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF). Rabbit VEGF-A Recombinant Protein is purified vascular endothelial growth factor A produced in yeast.

Rat VEGF-A Recombinant Protein
R00045-7	BosterBio	5ug/vial	EUR 259
Description: VEGF-A is member of the family of vascular endothelial growth factor (VEGF) proteins, which stimulate vasculogenesis and angiogenesis to restore oxygen supply to tissues. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF). Rat VEGF-A Recombinant Protein is purified vascular endothelial growth factor A produced in yeast.

Swine VEGF-A Recombinant Protein
R00045-8	BosterBio	5ug/vial	EUR 259
Description: VEGF-A is member of the family of vascular endothelial growth factor (VEGF) proteins, which stimulate vasculogenesis and angiogenesis to restore oxygen supply to tissues. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF). Swine VEGF-A Recombinant Protein is purified vascular endothelial growth factor A produced in yeast.

VEGF-A Polyclonal Conjugated Antibody
C41552	SAB	100ul	EUR 397

Human VEGF-A ELISA kit
CT529A	U-CyTech	5-plate	EUR 462

Recombinant Rat VEGF-A/VEGF164
CJ96-10ug	Novoprotein	10ug	EUR 168
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Recombinant Rat VEGF-A/VEGF164
CJ96-1mg	Novoprotein	1mg	EUR 2283
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Recombinant Rat VEGF-A/VEGF164
CJ96-500ug	Novoprotein	500ug	EUR 1613
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Recombinant Rat VEGF-A/VEGF164
CJ96-50ug	Novoprotein	50ug	EUR 405
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

VEGF-A ELISA KIT|Human
EF005092	Lifescience Market	96 Tests	EUR 689

Recombinant Human VEGF-A/VEGF165
C083-10ug	Novoprotein	10ug	EUR 202
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2.

Recombinant Human VEGF-A/VEGF165
C083-1mg	Novoprotein	1mg	EUR 2587
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2.

Recombinant Human VEGF-A/VEGF165
C083-500ug	Novoprotein	500ug	EUR 1826
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2.

Recombinant Human VEGF-A/VEGF165
C083-50ug	Novoprotein	50ug	EUR 496
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2.

Recombinant Human VEGF-A/VEGF121
C744-10ug	Novoprotein	10ug	EUR 202
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4.

Recombinant Human VEGF-A/VEGF121
C744-1mg	Novoprotein	1mg	EUR 2486
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4.

Recombinant Human VEGF-A/VEGF121
C744-500ug	Novoprotein	500ug	EUR 1613
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4.

Recombinant Human VEGF-A/VEGF121
C744-50ug	Novoprotein	50ug	EUR 496
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4.

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-Mu-48Tests	Reddot Biotech	48 Tests	EUR 429

The components discovered to be considerably related to seropositivity towards anti-Fasciola IgG antibody had been the age group of 18 years outdated and above with calculated odds ratio of three.2 instances (p=0.032) and the period of farming actions of greater than 5 years with calculated odds ratio of two.6 instances (p=0.036). In conclusion, Fasciola an infection is prevalent amongst cattle farm staff and dwellers in Kelantan.